Disease Info Card

Nonalcoholic Fatty Liver Disease

Information about Nonalcoholic Fatty Liver Disease: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Nonalcoholic Fatty Liver Disease

Most recent studies have shown that Nonalcoholic Fatty Liver Disease shares some biological mechanisms with carcinoma, cardiovascular-diseases, chronic-liver-disease, diabetes-mellitus, diabetes-mellitus-non-insulin-dependent, fatty-liver, fibrosis, hepatic-fibrosis, hepatitis, hypertensive-disease, inflammation, insulin-resistance, liver-carcinoma, liver-cirrhosis, liver-diseases, metabolic-syndrome-x, nonalcoholic-steatohepatitis, obesity, steatohepatitis, steatosis.

Among the many pathways, these few ones have gauged particular interests from scientists studying Nonalcoholic Fatty Liver Disease, and have been seen in publications frequently: Aging, Cell Activation, Cell Death, Coagulation, Cytokine Production, Excretion, Fatty Acid Oxidation, Glomerular Filtration, Gluconeogenesis, Glucose Homeostasis, Inflammatory Response, Insulin Secretion, Lipid Homeostasis, Lipid Oxidation, Lipid Storage, Pathogenesis, Regeneration, Reverse Transcription, Secretion, Transport

Quite a number of genes have been found to play important roles in Nonalcoholic Fatty Liver Disease, such as ADIPOQ, ALB, CRP, FASN, GGT1, GGT2, IL6, INS, KRT18, LEP, PNPLA3, PPARA, PPARG, RETN, SLC17A5, SREBF1, TG, TNF. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.